Oppenheimer Holdings, Inc. reissued their hold rating on shares of Affimed N.V. (NASDAQ:AFMD) in a research report report published on Friday morning.

Other equities research analysts also recently issued research reports about the company. Jefferies Group LLC reissued a hold rating and set a $2.50 price objective on shares of Affimed in a report on Thursday, July 27th. ValuEngine downgraded Affimed from a sell rating to a strong sell rating in a report on Friday, September 1st.

Shares of Affimed (NASDAQ:AFMD) remained flat at $$2.10 during mid-day trading on Friday. 362,100 shares of the company’s stock traded hands, compared to its average volume of 279,069. Affimed has a twelve month low of $1.65 and a twelve month high of $2.95. The company has a quick ratio of 6.39, a current ratio of 6.43 and a debt-to-equity ratio of 0.14.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AFMD. Virtu KCG Holdings LLC acquired a new stake in shares of Affimed during the 2nd quarter valued at $144,000. Creative Planning boosted its holdings in shares of Affimed by 7.7% during the 2nd quarter. Creative Planning now owns 70,000 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 5,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Affimed by 817.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 137,783 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 122,773 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Affimed during the 3rd quarter valued at $658,000. Finally, Nationwide Fund Advisors boosted its holdings in shares of Affimed by 4.6% during the 2nd quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock valued at $1,038,000 after acquiring an additional 22,172 shares in the last quarter. 43.31% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Affimed N.V. (AFMD) Receives “Hold” Rating from Oppenheimer Holdings, Inc.” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/affimed-n-v-afmd-receives-hold-rating-from-oppenheimer-holdings-inc/1729452.html.

About Affimed

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.